Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.57 |
| ▸ | TNKS | O95271 | 6/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.55 |
| ▸ | KRAS | P01116 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074928 | 0.86 | KRAS (0.46) | CHEK1TNKSTNKS2KRASPARP1 | |
| SCHEMBL23378336 | 0.80 | LIMK1 (0.55) | CHEK1TNKSTNKS2KRASPARP1 | |
| SCHEMBL259202 | 0.77 | PARP1 (0.53) | TNKSTNKS2KRASPARP1ALDH1A1 | |
| SCHEMBL23378412 | 0.76 | LIMK1 (0.48) | TNKSTNKS2KRASALDH1A1KDM4E | |
| SCHEMBL23378452 | 0.73 | LIMK1 (0.42) | KRASKDM4EPIK3CALIMK1CLK1 | |
| SCHEMBL23378173 | 0.73 | LIMK1 (0.41) | KRASKDM4EPIK3CALIMK1CLK1 | |
| SCHEMBL278692 | 0.72 | CDC7 (0.51) | TNKS2PARP1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5438893 | 0.71 | TNKS (0.65) | TNKSTNKS2PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL259214 | 0.71 | TNKS (0.49) | TNKSTNKS2PARP1ALDH1A1KDM4E | |
| SCHEMBL23378544 | 0.70 | PIK3CA (0.59) | ALDH1A1KDM4ESMN1; SMN2RAB9APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230084927-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD. (IL) | 2023-03-16 | — | — | US | disclosed |
| EP-4058027-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | Metabomed Ltd (IL) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021095032-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD (IL) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021095032-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD (IL) | 2021-05-20 | — | — | WO | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | CHEK1 326/4885TNKS 578/4885TNKS2 487/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | CHEK1 326/4885TNKS 578/4885TNKS2 487/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | CHEK1 326/4885TNKS 578/4885TNKS2 487/4885 |
| US-20230084927-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | SLC2A4, SLC2A1, SLC2A2 | CHEK1 378/4885TNKS 2991/4885TNKS2 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.